<SEC-DOCUMENT>0001004878-17-000045.txt : 20170228
<SEC-HEADER>0001004878-17-000045.hdr.sgml : 20170228
<ACCEPTANCE-DATETIME>20170227173837
ACCESSION NUMBER:		0001004878-17-000045
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170224
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170228
DATE AS OF CHANGE:		20170227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		17643506

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8kitem301nyse2-17.txt
<DESCRIPTION>8-K ITEM 3.01
<TEXT>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

     Date of Report (date of earliest event reported): February 24, 2017


                               CEL-SCI CORPORATION
              ---------------------------------------------------
             (Exact name of Registrant as specified in its charter)



       Colorado                       01-11889                  84-0916344
 --------------------            -------------------         ----------------
(State or other jurisdiction    (Commission File No.)       (IRS Employer
of incorporation)                                            Identification No.)


                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
              ---------------------------------------------------
          (Address of principal executive offices, including Zip Code)



       Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
              ---------------------------------------------------
          (Former name or former address if changed since last report)

<PAGE>

Item 3.01.  Other Events.

     On December 9, 2016,  the  Company  received  notice from the NYSE MKT (the
"Exchange")  indicating  that the Company  was not in  compliance  with  Section
1003(a) of the Exchange's  continued listing standards in the Company Guide. The
Company was afforded the opportunity to submit a plan to regain compliance,  and
on January 9, 2017 the Company submitted its plan to the Exchange.

     On February  24, 2017,  the Exchange  notified the Company that it accepted
the Company's plan of compliance and granted the Company an extension until June
11, 2018 to regain compliance with the continued listing standards.  The Company
will be subject to periodic review during the extension period.  Failure to make
progress  consistent  with the plan or to regain  compliance  with the continued
listing standards by the end of the extension period could result in the Company
being delisted from the NYSE MKT.

     On February 27, 2017,  the Company  issued a press release  announcing  its
receipt from the Exchange of its acceptance of the Company's plan of compliance.
The full text of this press release is attached as Exhibit 99.

Item 9.01.  Financial Statements anf Exhibits.

Exhibit     Description
-------     -----------

 99         Press Release dated February 27, 2017



                                       2
<PAGE>




                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:  February 27, 2017                     CEL-SCI CORPORATION



                                         By: /s/ Patricia B. Prichep
                                             ---------------------------------
                                             Patricia B. Prichep,
                                             Senior Vice President of Operations
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>form8kitem301ex99feb-17.txt
<DESCRIPTION>EXHIBIT 99 PRESS RELEASE
<TEXT>




                                   EXHIBIT 99




<PAGE>


8229 Boone Boulevard,
Suite 802                                            COMPANY CONTACT:
Vienna, VA  22182.  USA                              Gavin de Windt
Telephone (703) 506-9460                             CEL-SCI Corporation
www.cel-sci.com                                      (703) 506-9460

CEL-SCI Announces That the NYSE MKT Approves Plan

VIENNA,  VA, February 27, 2017 - CEL-SCI  Corporation  (NYSE MKT: CVM) announces
that the NYSE MKT (the  "Exchange")  has  accepted the  Company's  plan to bring
itself into compliance with the Exchange's continued listing standards.

The Company  previously  received  notice from the Exchange on December 9, 2016,
indicating  the Company is below  compliance  with Section  1003(a)(i),  Section
1003(a)(ii) and Section  1003(a)(iii)  since it reported a stockholders'  equity
deficit  as of June 30,  2016 and had a net losses in its 5 most  recent  fiscal
years ended  September  30, 2015.  The Company was afforded the  opportunity  to
submit a plan to regain compliance, and on January 9, 2017 the Company submitted
its plan to the Exchange.

On February  24, 2017 the  Exchange  notified  the Company  that it accepted the
Company's  plan of  compliance  and granted  the Company  until June 11, 2018 to
regain  compliance  with the continued  listing  standards.  The Company will be
subject  to  periodic  review  during  this  period.  Failure  to make  progress
consistent  with the plan or to regain  compliance  with the  continued  listing
standards by the end of the period could  result in the Company  being  delisted
from the NYSE MKT. The Company may then appeal a staff determination to initiate
such proceedings in accordance with the exchange's Company Guide.

About CEL-SCI Corporation

CEL-SCI's  work is focused on finding the best way to activate the immune system
to fight cancer and infectious  diseases.  The Company has operations in Vienna,
Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release  contains  forward-looking  statements  within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange Act of 1934, as amended.  When used in this press  release,
the words  "intends,"  "believes,"  "anticipated,"  "plans" and  "expects,"  and
similar expressions,  are intended to identify forward-looking  statements. Such
statements  are  subject  to risks and  uncertainties  that could  cause  actual
results to differ materially from those projected.  Such statements include, but
are not  limited  to,  statements  about the terms,  expected  proceeds,  use of
proceeds and closing of the offering.  Factors that could cause or contribute to
such  differences  include,  an  inability to  duplicate  the  clinical  results
demonstrated in clinical studies,  timely  development of any potential products
that  can be  shown to be safe and  effective,  receiving  necessary  regulatory
approvals,   difficulties  in  manufacturing  any  of  the  Company's  potential
products,  inability  to raise the  necessary  capital and the risk  factors set
forth from time to time in CEL-SCI's  filings with the  Securities  and Exchange
Commission,  including but not limited to its report on Form 10-K and 10-K/A for
the year ended  September  30, 2016.  The Company  undertakes  no  obligation to
publicly release the result of any revision to these forward-looking  statements
which may be made to reflect the events or  circumstances  after the date hereof
or to reflect the occurrence of unanticipated events.\
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
